Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies-Reference-Cited by-同舟云学术

Dasatinib: a potential tyrosine kinase inhibitor to fight against multiple cancer malignancies

Published:2023-05-10 Issue:6 Volume:40 Page:
ISSN:1559-131X
Container-title:Medical Oncology
language:en
Short-container-title:Med Oncol

Author:

Fauziya ,Gupta Akash,Nadaf Arif,Ahmad Shadaan,Hasan Nazeer,Imran Mohammad,Sahebkar Amirhossein,Jain Gaurav Kumar,Kesharwani Prashant^ORCID,Ahmad Farhan J.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s12032-023-02018-5.pdf

Reference120 articles.

1. McCormack PL, Keam SJ. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and philadelphia chromosome-positive acute lymphoblastic leukaemia. Drugs. 2011;71:1771–95. https://doi.org/10.2165/11207580-000000000-00000.

2. Niza E, Del Mar Noblejas-López M, Bravo I, Nieto-Jiménez C, Castro-Osma JA, Canales-Vázquez J, Lara-Sanchez A, Galán Moya EM, Burgos M, Ocaña A, Alonso-Moreno C. Trastuzumab-targeted biodegradable nanoparticles for enhanced delivery of dasatinib in HER2+ metastasic breast Cancer. Nanomaterials. 2019. https://doi.org/10.3390/nano9121793.

3. Ongoren S, Eskazan AE, Suzan V, Savci S, Erdogan Ozunal I, Berk S, Yalniz FF, Elverdi T, Salihoglu A, Erbilgin Y, Iseri SA, Ar MC, Baslar Z, Aydin Y, Tuzuner N, Ozbek U, Soysal T. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature. Hematology. 2018;23:212–20. https://doi.org/10.1080/10245332.2017.1385193.

4. Montemurro M, Cioffi A, Dômont J, Rutkowski P, Roth AD, von Moos R, Inauen R, Toulmonde M, Burkhard RO, Knuesli C, Bauer S, Cassier P, Schwarb H, Le Cesne A, Koeberle D, Bärtschi D, Dietrich D, Biaggi C, Prior J, Leyvraz S. Long-term outcome of dasatinib first-line treatment in gastrointestinal stromal tumor: a multicenter, 2-stage phase 2 trial (Swiss Group for Clinical Cancer Research 56/07). Cancer. 2018;124:1449–54. https://doi.org/10.1002/CNCR.31234.

5. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, Castaneda S, Cornelius LAM, Das J, Doweyko AM, Fairchild C, Hunt JT, Inigo I, Johnston K, Kamath A, Kan D, Klei H, Marathe P, Pang S, Peterson R, Pitt S, Schieven GL, Schmidt RJ, Tokarski J, Wen ML, Wityak J, Borzilleri RM. Discovery of N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658–61. https://doi.org/10.1021/JM049486A/SUPPL_FILE/JM049486ASI20041105_112036.PDF.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting senescence‐associated secretory phenotypes to remodel the tumour microenvironment and modulate tumour outcomes;Clinical and Translational Medicine;2024-09

2. Targeting oncogenic kinases: Insights on FDA approved tyrosine kinase inhibitors;European Journal of Pharmacology;2024-05

3. Dasatinib promotes muscle differentiation and disrupts normal muscle regeneration;International Journal of Medical Sciences;2024